- Home
- ILPT vs MGNX Comparison
ILPT vs MGNX Comparison
Compare ILPT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- MGNX
- Stock Information
- Founded
- ILPT 2017
- MGNX 2000
- Country
- ILPT United States
- MGNX United States
- Employees
- ILPT N/A
- MGNX N/A
- Industry
- ILPT Real Estate Investment Trusts
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- MGNX Health Care
- Exchange
- ILPT Nasdaq
- MGNX Nasdaq
- Market Cap
- ILPT 235.1M
- MGNX 257.3M
- IPO Year
- ILPT 2018
- MGNX 2013
- Fundamental
- Price
- ILPT $3.37
- MGNX $3.17
- Analyst Decision
- ILPT Buy
- MGNX Hold
- Analyst Count
- ILPT 2
- MGNX 10
- Target Price
- ILPT $10.00
- MGNX $7.17
- AVG Volume (30 Days)
- ILPT 351.3K
- MGNX 506.1K
- Earning Date
- ILPT 02-18-2025
- MGNX 11-05-2024
- Dividend Yield
- ILPT 1.23%
- MGNX N/A
- EPS Growth
- ILPT N/A
- MGNX N/A
- EPS
- ILPT N/A
- MGNX N/A
- Revenue
- ILPT $440,696,000.00
- MGNX $141,329,000.00
- Revenue This Year
- ILPT N/A
- MGNX $174.73
- Revenue Next Year
- ILPT $6.87
- MGNX N/A
- P/E Ratio
- ILPT N/A
- MGNX N/A
- Revenue Growth
- ILPT 1.36
- MGNX 16.68
- 52 Week Low
- ILPT $3.15
- MGNX $2.95
- 52 Week High
- ILPT $5.45
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- ILPT 35.88
- MGNX 41.22
- Support Level
- ILPT $3.60
- MGNX $3.10
- Resistance Level
- ILPT $3.78
- MGNX $3.45
- Average True Range (ATR)
- ILPT 0.15
- MGNX 0.20
- MACD
- ILPT -0.03
- MGNX -0.01
- Stochastic Oscillator
- ILPT 18.97
- MGNX 17.24
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).